338 related articles for article (PubMed ID: 26782292)
1. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
Kanzaki A; Kudo M; Ansai S; Peng WX; Ishino K; Yamamoto T; Wada R; Fujii T; Teduka K; Kawahara K; Kawamoto Y; Kitamura T; Kawana S; Saeki H; Naito Z
Int J Oncol; 2016 Mar; 48(3):1007-15. PubMed ID: 26782292
[TBL] [Abstract][Full Text] [Related]
2. IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.
Soddu S; Di Felice E; Cabras S; Castellanos ME; Atzori L; Faa G; Pilloni L
Eur J Histochem; 2013 Feb; 57(1):e6. PubMed ID: 23549465
[TBL] [Abstract][Full Text] [Related]
3. The potential role of abnormal E-cadherin and alpha-, beta- and gamma-catenin immunoreactivity in the determination of the biological behaviour of keratoacanthoma.
Papadavid E; Pignatelli M; Zakynthinos S; Krausz T; Chu AC
Br J Dermatol; 2001 Oct; 145(4):582-9. PubMed ID: 11703284
[TBL] [Abstract][Full Text] [Related]
4. The nuclear factor kappa B p50 subunit and cortactin as markers to distinguish between keratoacanthoma and well-differentiated squamous cell carcinoma.
Fujii M; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2011 Oct; 36(7):788-92. PubMed ID: 21883393
[TBL] [Abstract][Full Text] [Related]
5. Histopathological diagnosis of epithelial crateriform tumors: Keratoacanthoma and other epithelial crateriform tumors.
Ogita A; Ansai SI; Misago N; Anan T; Fukumoto T; Saeki H
J Dermatol; 2016 Nov; 43(11):1321-1331. PubMed ID: 27076258
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic neoplasms with squamous phenotype: actinic keratosis, keratoacanthoma and squamous cell carcinoma of the skin.
Krunic AL; Garrod DR; Madani S; Buchanan MD; Clark RE
Br J Cancer; 1998 Apr; 77(8):1275-9. PubMed ID: 9579833
[TBL] [Abstract][Full Text] [Related]
7. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma.
Kerschmann RL; McCalmont TH; LeBoit PE
Arch Dermatol; 1994 Feb; 130(2):181-6. PubMed ID: 8304756
[TBL] [Abstract][Full Text] [Related]
8. The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma.
Vasiljević N; Andersson K; Bjelkenkrantz K; Kjellström C; Månsson H; Nilsson E; Landberg G; Dillner J; Forslund O
Int J Cancer; 2009 May; 124(10):2361-6. PubMed ID: 19165861
[TBL] [Abstract][Full Text] [Related]
9. Amphiregulin overexpression results in rapidly growing keratinocytic tumors: an in vivo xenograft model of keratoacanthoma.
Billings SD; Southall MD; Li T; Cook PW; Baldridge L; Moores WB; Spandau DF; Foley JG; Travers JB
Am J Pathol; 2003 Dec; 163(6):2451-8. PubMed ID: 14633617
[TBL] [Abstract][Full Text] [Related]
10. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
Mukunyadzi P; Sanderson RD; Fan CY; Smoller BR
Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
[TBL] [Abstract][Full Text] [Related]
11. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry.
Biesterfeld S; Josef J
Anticancer Res; 2002; 22(5):3019-23. PubMed ID: 12530035
[TBL] [Abstract][Full Text] [Related]
12. Plasmacytoid dendritic cells in keratoacanthoma and squamous cell carcinoma: A blinded study of CD123 as a diagnostic marker.
Fraga GR; Chow P
J Cutan Pathol; 2020 Jan; 47(1):17-21. PubMed ID: 31449667
[TBL] [Abstract][Full Text] [Related]
13. Assessment of syndecan-1 (CD138) and Ki-67 expression for differentiating keratoacanthoma and squamous cell carcinoma.
Lammoglia-Ordiales L; Toussaint-Caire S; Contreras-Barrera M; Fonte-Avalos V; Rodriguez-Carreón AA; Rivera-Macias S; Dominguez-Cherit J
J Drugs Dermatol; 2013 Mar; 12(3):e53-8. PubMed ID: 23545927
[TBL] [Abstract][Full Text] [Related]
14. Keratoacanthoma and other types of squamous cell carcinoma with crateriform architecture: classification and identification.
Misago N; Inoue T; Koba S; Narisawa Y
J Dermatol; 2013 Jun; 40(6):443-52. PubMed ID: 23414327
[TBL] [Abstract][Full Text] [Related]
15. p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.
Kaabipour E; Haupt HM; Stern JB; Kanetsky PA; Podolski VF; Martin AM
Arch Pathol Lab Med; 2006 Jan; 130(1):69-73. PubMed ID: 16390241
[TBL] [Abstract][Full Text] [Related]
16. Differences between keratoacanthoma and squamous cell carcinoma using TGF-alpha.
Cabrijan L; Lipozencić J; Batinac T; Lenković M; Zgombić ZS
Coll Antropol; 2013 Mar; 37(1):147-50. PubMed ID: 23697265
[TBL] [Abstract][Full Text] [Related]
17. p53 protein expression and cell proliferation in non-neoplastic and neoplastic proliferative skin diseases.
Batinac T; Zamolo G; Jonjić N; Gruber F; Petrovecki M
Tumori; 2004; 90(1):120-7. PubMed ID: 15143984
[TBL] [Abstract][Full Text] [Related]
18. Glut-1 expression and in situ CD1a/CD57 immunologic deficit in keratoacanthoma and squamous cell carcinoma of immunocompetent patients.
Cabibi D; Aragona F; Guarnotta C; Rodolico V; Zerilli M; Belmonte B; Schillaci L; Aragona F
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):239-45. PubMed ID: 21475039
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin 10 and Ki-67 nuclear marker expression in keratoacanthoma and squamous cell carcinoma.
Basta-Juzbasić A; Klenkar S; Jakić-Razumović J; Pasić A; Loncarić D
Acta Dermatovenerol Croat; 2004; 12(4):251-6. PubMed ID: 15588557
[TBL] [Abstract][Full Text] [Related]
20. The role of p53, Ki-67 and laminin expression in the differential diagnosis of keratoacanthoma and well-differentiated SCC.
Turan G; Altun E; Aslan F; Kulahci O
Indian J Pathol Microbiol; 2019; 62(4):561-565. PubMed ID: 31611440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
